Gruenenthal Gmbh

Nycomed Austria Gmbh

Gruenethal Gmbh

Cambridge Bioclinical Limited

Medifron Dbt Inc.

Grunenthal Gmbh

Thomas Christoph

Klaus Schiene

Gregor Bahrenberg

Robert Frank

Jeewoo Lee

Derek John Saunders

Jean De Vry

Bernhard Lesch

Bernd Sundermann

Stefan Oberboersch

Nils Damann

Sven Frormann

Elmar Josef Friderichs

Hannelore Stockhausen

Klaus Linz

Sven Kuehnert

Stefanie Frosch

Ruth Jostock

Beatrix Merla

Wolfgang Schroeder

Stefan Schunk

Melanie Reich

Achim Kless

Tieno Germann

Michael Przewosny

Franz Rovenszky

Sabine Hees

Michael Hartmann

Babette-Yvonne Koegel

Corinna Sundermann

Wolfgang Schröder

Peter Kremminger

Michael Haurand

Sven Kühnert

Yong-Soo Kim

Myeong-Seop Kim

Edward Bijsterveld

Robert Frank-Foltyn

Robertson Towart

Ulrich Reinhold

Michael Engels

Petra Bloms-Funke

Saskia Zemolka

Marc Schiller

Dagmar Stimmeder

Dagmar Kaulartz

Sabine Karine Katrien Inghelbrecht

Thomas Tzschentke

Heinz Blaschke

Eva Wulsten

Babette-Yvonne Kögel

Michael Franz-Martin Engels

Michel Hamon

Harald Fellier

Stefan Oberbörsch

Roger Carolus Embrechts

Ulrich Feil

Clemens Gillen

Peter Esch

George Terence Evelyn Kealey

Murielle Meen

Jewoo Lee

Christopher Habermann

Jorg Berg

Hyung Chul Ryu

K-H Martin Schäfer

Florian Bender

Muriel Meen

Elmar Friderichs

Myeon-Seop Kim

Roger Carolus Augusta Embrechts

Sabine Karine Inghelbrecht

Eberhard Weihe

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro [cyclohexane-1,1&#x2032;-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an antidepressant.

Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano[3,4,b]indo]-4-amine and antidepressants

A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.

Pharmaceutical combination

The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof.

Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano[3,4,b]indol]-4-amine and a gabapentinoid

Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.

Substituted phenylureas and phenylamides as vanilloid receptor ligands

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an anticonvulsant selected from the group consisting of retigabin, lamotrigine, lacosamide, levetiracetam, carbamazepine, sultiame, phenacemide, felbamate, topiramate, pheneturide, brivaracetam, selectracetam, zonisamide, stiripentol, beclamide, mexiletin, ralfinamide, methylphenobarbital, phenobarbital, primidone, barbexaclone, metharbital, ethotoin, phenyloin, amino(diphenylhydantoin) valeric acid, mephenyloin, fosphenyloin, paramethadione, trimethadione, ethadione, ethosuximide, phensuximide, mesuximide, clonazepam, lorazepam, diazepam, clobazam, oxcarbazepine, eslicarbazepine, rufinamide, valproic acid, valpromide, aminobutyric acid, progabide, tiagabine, and the physiologically acceptable salts thereof.

Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano[3,4,b]indol]-4-amine and an anticonvulsant

Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4&#x2032;9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano[3,4,b]indol]-4-amine and a gabapentinoid

The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.

Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds, and a method of using these compounds in the treatment and/or inhibition of pain and further diseases and/or disorders mediated at least in part via the vanilloid receptor 1 (VR1/TRPV1).

Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands

Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.

Combination of selected opioids with muscarine antagonists for treating urinary incontinence

The invention relates to aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands

Vanilloid receptor ligand compounds corresponding to formula I: a process for producing such compounds, pharmaceutical compositions containing them, and the use of such compounds to treat pain and various other vanilloid receptor mediated conditions.

Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions

Vanilloid receptor ligand compounds corresponding to formula I: pharmaceutical compositions containing such compounds, a process for producing such compounds, and methods of using such compounds for treating or inhibiting pain and various other disorders or conditions.

Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions

The invention relates to amine substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands

Growing community of inventors

Aachen, Germany

Thomas Christoph